This article is more than 5 years old. Information may no longer be current.

Study initiated to evaluate SLT vs. topical medical therapy

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

LAS VEGAS — A prospective multi-center study has been initiated to answer the long-standing lasers-vs.-medication question, L. Jay Katz, MD, announced here at the First Annual Ocular Surgery News Symposium — Glaucoma: Improving Your Odds.

Dubbed the SLT/MED study, the protocol is randomized for patients and is U.S.-based. Patients will be randomized to receive selective laser trabeculoplasty (SLT) or a topical medical therapy as first-line therapy for the treatment of glaucoma. Medications are not specified. Researchers will use their current first-line medication of choice.

The study protocol includes a stepping regimen with increasing SLT treatment. SLT 360, SLT 180, SLT 180 with a 6 week to 4 month wait between each treatment.

Enrollment is ongoing.